Clinical trial
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer…
NCT00301925 · Institute of Cancer Research, United Kingdom, Other · Unknown status
Key facts
| NCT number | NCT00301925 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery |
| Official title | Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer (TACT2) |
| Acronym | TACT2 |
| Lead sponsor | Institute of Cancer Research, United Kingdom, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | pegfilgrastim, capecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate, adjuvant therapy |
| Enrollment | 4,400 |
| Start date | Dec 16, 2005 |
| Primary completion | Sep 1, 2024 |
| Completion | Sep 1, 2024 |
| First posted | Mar 13, 2006 |
| Last update posted | Aug 8, 2018 |
| Countries | United Kingdom |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: